Literature DB >> 7000827

Alterations in immunoregulatory T cell subsets in active systemic lupus erythematosus.

C Morimoto, E L Reinherz, S F Schlossman, P H Schur, J A Mills, A D Steinberg.   

Abstract

To determine whether imbalance among subsets of human T cells exists in patients with systemic lupus erythematosus (SLE), we analyzed peripheral blood lymphocytes in SLE patients during active and inactive stages of disease. For this analysis, we used monoclonal antibodies to the surface antigens of inducer (T4) and suppressor (T5/T8) T cell subsets, as well as a common T cell antigen (T3). In contrast to normal and inactive SLE patients, the percentage of T3+ cells was reduced in all active SLE patients. More importantly, there was a selective decrease in T5+/T8+ suppressor T cells in 12 of 14 active patients, including 1 of 2 patients with drug-induced SLE. Serial analysis of three SLE patients showed a significant correlation between the presence of T5+/T8+ subset and clinical disease activity in all patients. We conclude that aberrations in suppressor T cell subsets are an important correlate of disease in patients with SLE.

Entities:  

Mesh:

Year:  1980        PMID: 7000827      PMCID: PMC371557          DOI: 10.1172/JCI109948

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Suppressor T-cell abnormality in idiopathic systemic lupus erythematosus.

Authors:  N I Abdou; A Sagawa; E Pascual; J Hebert; S Sadeghee
Journal:  Clin Immunol Immunopathol       Date:  1976-09

2.  Abnormalities of delayed hypersensitivity in systemic lupus erythematosus.

Authors:  B H Hahn; K K Bagby; C K Osterland
Journal:  Am J Med       Date:  1973-07       Impact factor: 4.965

3.  Impaired delayed hypersensitivity in systemic lupus erythematosus.

Authors:  D A Horwitz
Journal:  Arthritis Rheum       Date:  1972 Jul-Aug

4.  Suppressor-cell dysfunction in systemic lupus erythematosus. Cells involved and in vitro correction.

Authors:  A Sagawa; N I Abdou
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

5.  Increased spontaneous activity of antibody-forming cells in the peripheral blood of patients with active SLE.

Authors:  D R Budman; E B Merchant; A D Steinberg; B Doft; M E Gershwin; E Lizzio; J P Reeves
Journal:  Arthritis Rheum       Date:  1977-04

6.  Fractionation of cells on a discontinuous Ficoll gradient. Study of subpopulations of human T cells using anti-T-cell antibodies from patients with systemic lupus erythematosus.

Authors:  W Glinski; M E Gershwin; A D Steinberg
Journal:  J Clin Invest       Date:  1976-03       Impact factor: 14.808

7.  Loss of suppressor T-lymphocyte function in patients with systemic lupus erythematosus (SLE).

Authors:  C Morimoto
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

8.  Suppressor function of peripheral blood mononuclear cells in normal individuals and in patients with systemic lupus erythematosus.

Authors:  B Bresnihan; H E Jasin
Journal:  J Clin Invest       Date:  1977-01       Impact factor: 14.808

9.  Studies of immune functions of patients with systemic lupus erythematosus. I. Dysfunction of suppressor T-cell activity related to impaired generation of, rather than response to, suppressor cells.

Authors:  T Sakane; A D Steinberg; I Green
Journal:  Arthritis Rheum       Date:  1978 Jul-Aug

10.  In vitro TNP-specific antibody formation by peripheral lymphocytes from patients with systemic lupus erythematosus.

Authors:  C Morimoto; T Abe; M Hara; M Homma
Journal:  Scand J Immunol       Date:  1977       Impact factor: 3.487

View more
  58 in total

1.  Flow cytometric analysis of peripheral blood lymphocytes in ulcerative colitis and Crohn's disease.

Authors:  M Senju; F Hulstaert; J Lowder; D P Jewell
Journal:  Gut       Date:  1991-07       Impact factor: 23.059

2.  Diminished response to an inhibitory signal in lymphocytes from patients with systemic lupus erythematosus.

Authors:  M Salata; J Golbus; B C Richardson
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

3.  Monoclonal antibody investigation in rheumatoid arthritis: presence of a T cell subpopulation bearing a double marker.

Authors:  G Lapadula; M Covelli; R Numo; G Tricarico; G Amendoni; C Berlingerio
Journal:  Clin Rheumatol       Date:  1984-06       Impact factor: 2.980

4.  An immunohistological study of secondary Sjögren's syndrome.

Authors:  D A Isenberg; D Rowe; A Tookman; A Hopp; M Griffiths; E Paice; J Stewart; P C Beverley
Journal:  Ann Rheum Dis       Date:  1984-06       Impact factor: 19.103

5.  Perforin mRNA expression in the inflamed tissues of NZB/W F1 lupus mice decreases with methylprednisolone treatment.

Authors:  T Nakamura; I Ebihara; Y Tomino; K Okumura; H Koide
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

6.  Relationship between systemic lupus erythematosus T cell subsets, anti-T cell antibodies, and T cell functions.

Authors:  C Morimoto; E L Reinherz; J A Distaso; A D Steinberg; S F Schlossman
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

7.  Loss of suppressor T-cells in active inflammatory bowel disease.

Authors:  N J Godin; D B Sachar; R Winchester; C Simon; H D Janowitz
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

8.  T lymphocyte interaction with immunoglobulin G antibody in systemic lupus erythematosus.

Authors:  K Okudaira; R P Searles; K Tanimoto; Y Horiuchi; R C Williams
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

9.  Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus.

Authors:  J Alcocer-Varela; D Alarcón-Segovia
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

10.  Serum soluble interleukin 2 receptor in systemic lupus erythematosus: effects of disease activity and infection.

Authors:  K L Wong; R P Wong
Journal:  Ann Rheum Dis       Date:  1991-10       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.